Juvenescence acquires AI drug discovery company Ro5

Juvenescence

Juvenescence acquired Ro5, an AI-driven drug discovery company with a proprietary biomedical knowledge graph of over 85 million nodes and 400 million relationships, plus an AI chemistry platform for compound discovery and optimization. The acquisition strengthens Juvenescence's R&D capabilities as part of its broader partnership with Abu Dhabi's M42.

• Ro5's biomedical knowledge graph contains over 85 million nodes and approximately 400 million relationships mapping biological associations.
• Platform includes AI chemistry tools for rapid compound discovery and design from hit identification through lead optimization.
• Acquisition accelerates development of therapeutics targeting cognition, cardio-metabolism, immunity, and cellular repair.